Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
City A.M. | London's Business Newspaper - News, Opinion, & Anal…
May 12, 2026
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. The live webcast can be [...]
Discussion in the ATmosphere